Precision medicine for metastatic breast cancer--limitations and solutions.
about
The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusBridging academic science and clinical research in the search for novel targeted anti-cancer agentsToward precision medicine of breast cancerRecent Advances of Light-Mediated Theranostics.Multiple network algorithm for epigenetic modules via the integration of genome-wide DNA methylation and gene expression data.Circulating Tumor DNA as Biomarkers for Cancer Detection.Optofluidic device for the quantification of circulating tumor cells in breast cancer.Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.Immunotherapy in glioblastoma: emerging options in precision medicineTransposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression.Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.Genomic Evolution of Breast Cancer Metastasis and Relapse.Towards efficiency in rare disease research: what is distinctive and important?Catalog of genetic progression of human cancers: breast cancer.Reverse Phase Protein Microarrays.Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Toward Precision Healthcare: Context and Mathematical ChallengesEntropy-based Consensus Clustering for Patient Stratification.Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.Barriers preventing the adoption of comprehensive cancer genomic profiling in the clinic.Engagement of the medical-technology sector with society.Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy.Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Comprehensive benchmarking of SNV callers for highly admixed tumor data.Sustained accuracy improvement in intraocular lens power calculation with the application of quality control circle.Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet.PedAM: a database for Pediatric Disease Annotation and Medicine.Packaging and transfer of mitochondrial DNA via exosomes regulate escape from dormancy in hormonal therapy-resistant breast cancer.Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.Exosomal microRNA: a novel biomarker for breast cancer.Targeted tumor detection: guidelines for developing biotinylated diagnostics.Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study.
P2860
Q26740184-1E0E6D69-3178-41E4-9248-55EC53B908B4Q26771396-DA0D3019-E6C7-414C-81F7-A73F378ACC8BQ28073967-E307F5AF-A223-462A-85BD-D2678567BF02Q28077517-1DAD7836-7696-4283-8C36-B5AF5F5EDFF1Q31157831-EE8142A3-ACFA-40D2-83CA-3D4E292AF9A4Q33632125-22A73F2E-91C3-482D-8F36-DD313ABEB75FQ33808137-DDDAF15D-8D18-4EC6-B4A5-A13932A4BF46Q34529131-08E71C14-5BA1-4501-B9EE-29F5F8F73B51Q37050960-A6D9E232-585C-454B-8DFF-6D45DC49BCC0Q37473990-A7C09A21-5D12-4820-ADB0-898E05373F0DQ37580359-B1F98C69-75F0-4898-A529-80B1CD3FCA18Q38623761-9EE5A56F-A228-422D-A8BB-1B724FAE7492Q38714572-C679BC73-87FA-4578-9FF2-BFA53BC1CFD4Q38764251-9518C3FF-AA0B-4DD4-B0B6-A912B1CF62F2Q38787411-420A09FF-D83B-4A77-ADE6-5BB2ED9D2195Q38818107-F55E5B15-BFA4-4BF6-ADAE-43AD4DB8F4B0Q38825945-A32A74B8-F5BB-41BC-95D6-2AB3FE4CEEEDQ38854423-2A2E9D7B-5D21-4293-9D81-9A372EE28D87Q38860341-E338D23F-BAEE-4EBC-B57C-A862B9738CAFQ38888022-09AD56CC-ACE0-4155-A772-C8B688057B30Q39187437-8E853CD0-338C-497E-9A17-DC05285B4EB3Q39237394-00F1FCCD-45BB-40E3-83A1-F5EDFB8A8C48Q39239100-9D6A7FB8-5892-4BB1-8C21-A2D21ED8B679Q40203060-7C102A63-3EF7-4C46-9EBD-75FB887B9883Q41459790-43A48A34-23A1-4EF7-89C9-5ED4D5EEB1F1Q42204343-9B6F0BD0-B8B9-44CC-826C-7F125CFDA3D4Q42700663-2D7A8697-2AA0-463E-B40A-9FE73BECB3B9Q42705197-465E2781-D9C6-4ED9-BE24-C717E089763FQ43159039-AE25F937-3C63-4BA7-9D87-408775EC6955Q46509951-95FBA989-C5C1-4CA4-AE79-B19F27EAD2AFQ47109110-97BC91CD-E621-44CC-B51E-C5252F803C23Q47118733-8ED0DCFA-17F1-4416-BF8F-C3530C3C2D94Q47162272-80AE2BE9-2CC7-4976-9796-135C49BF515DQ47556879-6098832D-5298-4A18-98F7-B63626E3A241Q47832818-8981B4DC-2C30-49F5-BDA9-16719B344E12Q48295925-4D593664-89CC-48EE-AC63-C3744B2D4E41Q49179749-674ACB46-2949-497F-90F4-651A27295EEBQ49593660-22C51F30-A8B8-433C-AFC3-1D9F64581B91Q52575440-F90725ED-3C0A-4F95-9678-C22289129A4FQ55266544-92D4C1F8-505E-450F-8021-209C99B46C88
P2860
Precision medicine for metastatic breast cancer--limitations and solutions.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Precision medicine for metastatic breast cancer--limitations and solutions.
@en
type
label
Precision medicine for metastatic breast cancer--limitations and solutions.
@en
prefLabel
Precision medicine for metastatic breast cancer--limitations and solutions.
@en
P2093
P2860
P50
P1476
Precision medicine for metastatic breast cancer--limitations and solutions
@en
P2093
Cecile Vicier
Celine Lefebvre
Herve Bonnefoi
Monica Arnedos
P2860
P304
P356
10.1038/NRCLINONC.2015.123
P407
P577
2015-07-21T00:00:00Z